News & Events

This proposed S-1 offering prospectus relates to the offering of 47,000,000 shares of common stock of Ludwig Enterprises, Inc. The Offering document is requesting but has not yet received final SEC approval. Click Here To Download

Sparks, NV – March 20, 2023:  Ludwig Enterprises, Inc., OTC: LUDG,(Ludwig - The Genomics LanguageCompany ™) is pleased to announce itintends to file, in the second quarter of 2023,a Non-OfferingProspectus to enable the Companyto be listed on the Canadian Stock Exchange (CSE). “This corporate arrangement creates a great opportunity for Ludwig,” says Chief Science Officer Marvin S. Hausman MD.  “Ludwig Enterprises and its subsidiary Precision Genomics have designed a genomicmRNA microarray assay that measures 48 different biomarkers of chronic inflammation

Sparks, NV – March 11, 2023:  Ludwig Enterprises, Inc. (The Genomics Language Company™) and its subsidiary Precision Genomics has attracted significant clinical interest in its patent pending mRNA Inflammatory Index™ which measures inflammatorybiomarkers that are associated with chronic diseases such as cancer, diabetes and heart disease. To date Precision Genomics has collected and is testing over 1700 samples from 28 different medical clinics along with detailed patient medical history.  The company is receiving over 100 samples each month.  The World

February 9, 2023 – Orlando, Florida:  Marvin Hausman MD, Chief Medical Officer ofLudwig Enterprises, Inc. and creator of the mRNA Inflammatory Index, lectured University of Central Florida graduate and pre-med students on the role of chronic inflammation in the development of diseases and how mRNA biomarkers may be the key to early detection of inflammation and the prevention of chronic illness.  Chronic illnesses account for 70% of the deaths in the United States.  There is growing evidence of a link

Sparks Nevada/February 9, 2023:  “Chronic inflammation is a silent disorder.”  Writes Dr. Marvin S. Hausman MD in his white paper Inflammation: A Unifying Causation of Disease - Nutritional Intervention. “All people are being bombarded daily with chronic inflammation which is slowly waging a warof attrition on our tissues and organs.  Picture air and water pollution, ionizing radiation from the sun, smoking, automobile emissions, etc. Most doctors only focus on observable inflammatory disease and symptoms in specific organs while the rest

This is One More Step in Ludwig's Planned Path to an NYSE or NASDAQ Listing. SPARKS, NV / ACCESSWIRE / January 12, 2023 / (OTC PINK:LUDG) Ludwig Enterprises Inc., "The Genomics Language Company" ™ the parent company of Precision Genomics Inc., and mRNA for Life Inc., is pleased to announce that they have begun the application process to be approved to trade on the OTCQB Market. This is a significant step towards achieving the company's goal of up-listing to the NYSE. The

Ludwig Enterprises Receives IRB Approval on Bladder Cancer StudymRNA Technology to Assess Patient Response to BCG Immunotherapy Treatment SPARKS, NV / ACCESSWIRE / January 3, 2023 / (OTC PINK:LUDG) Ludwig Enterprises,Inc., with its wholly owned subsidiary, Precision Genomics, Inc., creators of the mRNA Inflammatory Index™ (patent pending) which measures 48 different biomarkers of chronic inflammation, is pleased to announce Institutional Review Board (IRB) approval of a study titled "Using Measurements of mRNA and Elisa-based Cytokine/Protein Indices to Evaluate Pre- and Post-

Dr. Hausman Addressed How Precision Genomics mRNA technology can be a real breakthrough for significant chronic diseases. SPARKS, NV / ACCESSWIRE / November 16, 2022 / Precision Genomics, a Ludwig Enterprise Company (OTC:LUDG), is pleased to announce a SEQUIRE Spotlight featuring Dr. Marvin S. Hausman M.D. SEQUIRE Spotlight- Host Jonathan Miller interviews Chief Science Officer: Dr. Marvin S. Hausman. The featured interview includes in-depth information about the company's recent patent filing, upcoming bladder cancer study and the companies moves towards filing